about
Best strategies for global HCV eradication.Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors.Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.New antiviral therapies for chronic hepatitis CRigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses.INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agentsCharacteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients.Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Infections and the liver.A brief history of hepatitis milestones.HCV core protein and virus assembly: what we know without structures.Update on the Development of Anti-Viral Agents Against Hepatitis C.Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.Synthesis and anti-HCV entry activity studies of β-cyclodextrin-pentacyclic triterpene conjugates.Synthesis and evaluation of novel potent HCV NS5A inhibitorsGenetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs.Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV InfectionNew real-time-PCR method to identify single point mutations in hepatitis C virus.All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses.
P2860
Q27693824-5D567615-7FFE-4CFD-9A20-5F3B9219383EQ30541731-55304FC3-8008-4B06-9496-5D91A74B148AQ34022926-43AE2053-61CB-4CB5-90AC-9D802E2D8826Q34130399-E9C60B7D-2339-4E56-BB89-CF18A2A5F86BQ34182763-244B7A44-E3CF-4227-A93E-58108FE19DABQ34933094-2E5BC1FE-94AC-4A4D-896C-C522CA304EF2Q35026553-1C91E0AD-BDA5-4CB5-9BE2-69D3A80DDC24Q35085469-88F9B27E-3336-44FC-9504-43F4071CF1C7Q36667039-FA2F31E8-A80F-4E44-8DF0-38A49D582167Q36667165-40C20FAD-627B-405A-86F7-247F53E69BD4Q37300442-FA200486-EBAF-40D0-B97D-6718D1C49B07Q37335626-84EBD9D2-E4D6-4DEE-92CE-8C31A0BF2F31Q37898411-B30CDED8-058C-4548-93F9-656E6664ECD4Q38174247-2DA31A01-7018-46E3-B277-450937640FF8Q38190014-506DDFED-984B-4949-B5B7-C314B8664C5BQ38584271-C5AFBF32-4B1A-487D-B892-237B5A1A700DQ38660421-CAB9C76F-6902-4A77-9C84-6AE9B148EE7EQ39016028-FB8C2590-7AA7-493E-8802-CA212C034CC7Q39330313-B0137A62-63E8-41FC-BAB1-631E565D8F6EQ39641275-75C01401-7412-4AA6-B16C-155BFCFDE0F6Q39792685-8DF7166E-6232-4429-A5E9-BEB7E50ABB32Q40422658-69ADF59E-577C-4D36-A776-393DE4CB5AF2Q42251203-53E1D900-D9BD-41ED-AF77-F13EFB18C0E0
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HCV drug discovery aimed at viral eradication.
@en
HCV drug discovery aimed at viral eradication.
@nl
type
label
HCV drug discovery aimed at viral eradication.
@en
HCV drug discovery aimed at viral eradication.
@nl
prefLabel
HCV drug discovery aimed at viral eradication.
@en
HCV drug discovery aimed at viral eradication.
@nl
P2093
P2860
P1476
HCV drug discovery aimed at viral eradication.
@en
P2093
C Gavegnano
R F Schinazi
P2860
P356
10.1111/J.1365-2893.2009.01246.X
P577
2009-12-18T00:00:00Z